Day: February 25, 2021

 ►     The Company will collaborate with Professor Jérôme Boursier, M.D., Ph.D, a renowned scientist in the field of non-invasive diagnosis of liver lesions in chronic liver diseases ►     The collaboration aims at developing one or several biomarkers or a composite biomarker score to identify patients responding to lanifibranor with regards to NASH resolution and fibrosis improvement ►     The biomarker data from the NATIVE Phase IIb clinical trial with lanifibranor in NASH will be used as a first validation dataset and the lanifibranor biomarker signature would then be validated during upcoming NATIV3 Phase III clinical trial             Daix (France), February 25, 2021 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment...

 ►     Inventiva collaborera avec le professeur Jérôme Boursier, M.D., Ph.D., scientifique reconnu dans le domaine du diagnostic non-invasif des lésions hépatiques dans les maladies chroniques du foie ►     Cette collaboration vise à développer un ou plusieurs biomarqueurs ou un score combinant plusieurs biomarqueurs pour identifier les patients chez lesquels lanifibranor conduit à une résolution de la NASH et à une amélioration de la fibrose ►     Les biomarqueurs de l’étude clinique de Phase IIb NATIVE avec lanifibranor dans la NASH seront utilisées comme premières données de validation et la signature biomarqueur de lanifibranor sera ensuite validée lors de l’étude clinique de Phase III NATIV3 à venirDaix (France), 25 février 2021 – Inventiva (Euronext Paris et Nasdaq : IVA), société biopharmaceutique spécialisée dans le développement...

– Prioritizing next generation, more potent core inhibitors, triple combinations with complementary mechanisms of action, and expanding research programs to advance multiple candidates against novel targets– Extends cash runway into 2023– Company to host conference call today at 5:00 p.m. ET/2:00 p.m. PTSOUTH SAN FRANCISCO, Calif., Feb. 25, 2021 (GLOBE NEWSWIRE) — Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV), today announced that it is foregoing its plans to initiate Phase 3 registrational studies of vebicorvir (VBR, or ABI-H0731) as a chronic suppressive therapy (CST) to concentrate its research and development efforts on finite and curative HBV therapies. As part of this focused strategy on finite and curative...

Company Plans to Meet with FDA in Q1 to Discuss Results of GALACTIC-HFEnrollment Completed in Cohort 2 of REDWOOD-HCM; Results Expected Mid-YearCompany Provides 2021 Financial Guidance; More Than Two Years of Cash RunwaySOUTH SAN FRANCISCO, Calif., Feb. 25, 2021 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) reported financial results for the fourth quarter and full year 2020. Net loss for the fourth quarter was $43.9 million or $0.62 per share and the net loss for the year 2020 was $127.3 million or $1.97 per share. Net loss for the fourth quarter of 2019 was $30.6 million or $0.52 per share and net loss for the year 2019 was $121.7 million or $2.11 per share. Cash, cash equivalents and investments totaled $501.0 million at December 31, 2020.“In the fourth quarter, we were pleased to present the results of GALACTIC-HF...

        NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES.TORONTO, Feb. 25, 2021 (GLOBE NEWSWIRE) — Field Trip Health Ltd. (CSE: FTRP; FTRP.WT; OTCQX: FTRPF) (“Field Trip“), a leader in the development and delivery of psychedelic therapies, is pleased to announce it has entered into an agreement with Bloom Burton Securities Inc. (“Bloom Burton” or the “Lead Underwriter“) on behalf of a syndicate of underwriters (together with the Lead Underwriter, the “Underwriters“), pursuant to which the Underwriters have agreed to purchase, on a “bought deal” basis 7,692,310 common shares (the “Common Shares“) of the Company at a price of $6.50 per Common Share (the “Issue Price“), for aggregate gross proceeds of...

WILMINGTON, Del., Feb. 25, 2021 (GLOBE NEWSWIRE) — WSFS Financial Corporation (Nasdaq: WSFS), the parent company of WSFS Bank, announced that it will be added to the S&P SmallCap 600 Index, effective March 1, 2021. The S&P SmallCap 600 measures the small-cap segment of the U.S. equity market and consists of 600 domestic stocks selected by Standard & Poor’s Index Committee based on several factors, including financial performance and market capitalization.  “Being added to the S&P SmallCap 600 reaffirms our commitment to long term growth and sustainable high performance as the largest, locally headquartered bank in the Greater Philadelphia and Delaware markets. Our strategy: Engaged Associates, living our culture, making a better life for all we serve, underpins our business model and drives our success,”...

All amounts in U.S. dollars unless otherwise stated TORONTO, Feb. 25, 2021 (GLOBE NEWSWIRE) — The Board of Directors of Onex Corporation (TSX: ONEX) today declared a first-quarter dividend of C$0.10 per Subordinate Voting Share payable on April 30, 2021 to shareholders of record on April 9, 2021.For further information:Emilie BlouinDirector, Shareholder Relations and CommunicationsTel: +1 416.362.7711Onex Website: www.onex.com

ISLANDIA, N.Y. and LITTLETON, Colo., Feb. 25, 2021 (GLOBE NEWSWIRE) — Intrado Corporation (“Intrado”), and DISH Network Corporation (NASDAQ: DISH) (“DISH”) today announced an agreement for 911 call routing to support DISH’s cloud-native 5G wireless service, the first of its kind in the U.S.Successfully routing and delivering a 911 call is a foundational and vital requirement for any wireless communication network. Selecting Intrado for end-to-end 911 call delivery is an important milestone in DISH’s buildout of a truly unique 5G network, while helping public safety advance with the latest communications technologies.“We selected Intrado based on their longstanding reputation as a trusted provider of world class 911 solutions for both the telecommunications and public safety industries,” said Jeff McSchooler, DISH executive vice...

PALO ALTO, Calif., Feb. 25, 2021 (GLOBE NEWSWIRE) —First quarter GAAP diluted net earnings per share (“EPS”) of $0.83, above the previously provided outlook of $0.58 to $0.64 per shareFirst quarter non-GAAP diluted net EPS of $0.92, above the previously provided outlook of $0.64 to $0.70 per shareFirst quarter net revenue of $15.6 billion, up 7.0% from the prior-year periodFirst quarter net cash provided by operating activities of $1.0 billion, free cash flow of $0.9 billionFirst quarter returned $1.6 billion to shareholders in the form of share repurchases and dividendsNotes to tableInformation about HP Inc.’s use of non-GAAP financial information is provided under “Use of non-GAAP financial information” below.Net revenue and EPS resultsHP Inc. and its subsidiaries (“HP”) announced fiscal 2021 first...